Education
About Us
Working with TipRanks
Follow Us
Psyence Group (TSE:PSYG)
:PSYG
PSYG Stock Chart & Stats
Day’s Range― - ―
52-Week RangeC$0.11 - C$0.38
Previous CloseN/A
Volume20.00K
Average Volume (3M)4.05K
Market Cap
C$2.58M
Enterprise ValueC$1.17M
Total Cash (Recent Filing)C$803.84K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.81
Next Earnings
Nov 26, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding15,638,267
10 Day Avg. Volume830
30 Day Avg. Volume4,049
Financial Highlights & Ratios
PEG Ratio0.05
Price to Book (P/B)1.43
Price to Sales (P/S)0.00
P/FCF Ratio-0.33
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Psyence Group News
PSYG FAQ
What was Psyence Group’s price range in the past 12 months?
Psyence Group lowest stock price was C$0.10 and its highest was C$0.38 in the past 12 months.
What is Psyence Group’s market cap?
Psyence Group’s market cap is C$2.58M.
When is Psyence Group’s upcoming earnings report date?
Psyence Group’s upcoming earnings report date is Nov 26, 2025 which is in 54 days.
How were Psyence Group’s earnings last quarter?
Currently, no data Available
Is Psyence Group overvalued?
According to Wall Street analysts Psyence Group’s price is currently Overvalued.
Does Psyence Group pay dividends?
Psyence Group does not currently pay dividends.
What is Psyence Group’s EPS estimate?
Psyence Group’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Psyence Group have?
Psyence Group has 15,638,267 shares outstanding.
What happened to Psyence Group’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Psyence Group?
Currently, no hedge funds are holding shares in TSE:PSYG
Company Description
Psyence Group
Psyence Group (PSYG) is a biotechnology company focused on advancing psychedelic therapy and natural-based medicine. The company operates in the life sciences sector, leveraging the therapeutic potential of psychedelic compounds to address mental health issues and neurological disorders. Psyence’s core products and services include the development of natural psilocybin-based therapies, cultivating and processing psilocybin mushrooms, and conducting clinical trials to establish the efficacy and safety of their treatments.
Technical Analysis
Braxia Scientific
―
New Leaf Ventures
―
Entheon Biomedical
―
Silo Wellness Inc
―
Revitalist Lifestyle & Wellness Ltd
―
Options Prices
Currently, No data available
---